SCPH vs. RGLS, RENB, IVA, SKYE, ACET, IXHL, CRVO, VERU, TRVI, and GOSS
Should you be buying scPharmaceuticals stock or one of its competitors? The main competitors of scPharmaceuticals include Regulus Therapeutics (RGLS), Renovaro (RENB), Inventiva (IVA), Skye Bioscience (SKYE), Adicet Bio (ACET), Incannex Healthcare (IXHL), CervoMed (CRVO), Veru (VERU), Trevi Therapeutics (TRVI), and Gossamer Bio (GOSS). These companies are all part of the "pharmaceutical preparations" industry.
Regulus Therapeutics (NASDAQ:RGLS) and scPharmaceuticals (NASDAQ:SCPH) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, community ranking, media sentiment, institutional ownership, dividends, valuation and risk.
Regulus Therapeutics has higher earnings, but lower revenue than scPharmaceuticals. scPharmaceuticals is trading at a lower price-to-earnings ratio than Regulus Therapeutics, indicating that it is currently the more affordable of the two stocks.
Regulus Therapeutics received 324 more outperform votes than scPharmaceuticals when rated by MarketBeat users. However, 66.10% of users gave scPharmaceuticals an outperform vote while only 63.49% of users gave Regulus Therapeutics an outperform vote.
Regulus Therapeutics has a beta of 1.57, meaning that its stock price is 57% more volatile than the S&P 500. Comparatively, scPharmaceuticals has a beta of 0.06, meaning that its stock price is 94% less volatile than the S&P 500.
92.4% of Regulus Therapeutics shares are held by institutional investors. Comparatively, 89.5% of scPharmaceuticals shares are held by institutional investors. 8.4% of Regulus Therapeutics shares are held by insiders. Comparatively, 4.7% of scPharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
In the previous week, Regulus Therapeutics had 1 more articles in the media than scPharmaceuticals. MarketBeat recorded 2 mentions for Regulus Therapeutics and 1 mentions for scPharmaceuticals. scPharmaceuticals' average media sentiment score of 0.54 beat Regulus Therapeutics' score of 0.00 indicating that Regulus Therapeutics is being referred to more favorably in the media.
Regulus Therapeutics presently has a consensus target price of $7.25, suggesting a potential upside of 209.83%. scPharmaceuticals has a consensus target price of $19.33, suggesting a potential upside of 337.41%. Given Regulus Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe scPharmaceuticals is more favorable than Regulus Therapeutics.
Regulus Therapeutics has a net margin of 0.00% compared to Regulus Therapeutics' net margin of -403.22%. Regulus Therapeutics' return on equity of -97.18% beat scPharmaceuticals' return on equity.
Summary
Regulus Therapeutics beats scPharmaceuticals on 10 of the 17 factors compared between the two stocks.
Get scPharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SCPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SCPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
scPharmaceuticals Competitors List
Related Companies and Tools
